Celltrion said it applied to the European Medicine Agency's for marketing approval of CT-P17, a biosimilar referencing AbbVie's Humira, reported The Korea Herald.
If approved, CT-P17 would add to Celltrion's portfolio for rheumatoid arthritis and inflammatory bowel disease treatments, alongside the company's Remicade biosimilar Remsima.
"We believe CT-P17 has differentiated value from existing Humira biosimilars, with high market expectations," Celltrion said, adding that it expects to launch the product in Europe in about a year's time.
Apart from CT-P17, Celltrion is also carrying out Phase III testing on a biosimilar version of Roche's Avastin, dubbed CT-P16, for metastatic colorectal cancer, metastatic breast cancer and non-small-cell lung cancer indications.
In regards to Novartis' asthma and rash treatment Xolair, Celltrion is evaluating CT-P39 as a potential biosimilar.
To read more NewsPoints articles, click here.